A new report released today by BioBeat entitled “50 Movers & Shakers in BioBusiness 2019” includes five women from organisations based at Stevenage Bioscience Catalyst (SBC) as well as two Board members.
The report highlights the top female talent in the pharma and biotech sectors within the UK.
The report focuses on the impact of individuals in five key areas, namely science, finance, collaboration, patient impact and infrastructure. The SBC-based individuals which spanned the segments are:
Sally Ann Forsyth, CEO, Stevenage Bioscience Catalyst
Veronique Bouchet, Chief Medical Officer, RowAnalytics and SBC Board member
Melanie Lee, CEO, LifeArc
Jane Whitrow, VP Business Operations, Freeline Therapeutics
Pauline Stasiak, Investment Principal, LifeArc Seed Fund
Jane Robertson, Chief Medical Ofﬁcer, Achilles Therapeutics
Anna Outhwaite, Head, ATTC Network Coordination, Cell and Gene Therapy Catapult
The 50 Movers and Shakers report has been released in advance of the BioBeat19 Summit: Accelerating Cell and Gene Therapy, which will be hosted by GSK and SBC on Tuesday 19 November 2019. Emma Walmsley, CEO at GSK will deliver the keynote address, followed by discussions with leading women from across the cell and gene therapy landscape examining the journey from science to patients, and the value of these transformational therapies.
Dr Sally Ann Forsyth, CEO at SBC, commented “It is an honour to be included amongst this list of exceptional women from across the sector. We are proud that SBC is home to so many of this year’s Movers and Shakers. I look forward to further showcasing our talents when we co-host the BioBeat19 event later this month.”
For more information go to https://www.stevenagecatalyst.com/news/new-report-shows-more-10-uks-top-female-biobusines/